AACR Annual Meeting

The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.